S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Cytokinetics (CYTK) Stock Price, News & Analysis

$78.02
+2.43 (+3.21%)
(As of 02/23/2024 ET)
Today's Range
$75.86
$79.49
50-Day Range
$35.72
$108.06
52-Week Range
$25.98
$110.25
Volume
1.74 million shs
Average Volume
1.67 million shs
Market Capitalization
$7.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.94

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
5.2% Downside
$73.94 Price Target
Short Interest
Healthy
14.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.51mentions of Cytokinetics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$8.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.94) to ($4.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

318th out of 943 stocks

Pharmaceutical Preparations Industry

137th out of 431 stocks


CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

CYTK Mar 2024 79.000 put
CYTK Mar 2024 125.000 call
We Could Be Less Than 3 Months Out from an AI Superevent
According to one of the world’s top AI scientists, there’s a major event coming as soon as three months from today that could cause expensive tech stocks like Microsoft, Google, and NVIDIA to double or triple in price in the months ahead… but whatever you do, don’t go all in on big tech before you have all the details.
CYTK Feb 2024 84.000 call
Cytokinetics (CYTK) Scheduled to Post Quarterly Earnings on Tuesday
CYTK Feb 2024 72.000 put
CYTK Feb 2024 85.500 call
CYTK Feb 2024 80.500 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CYTK Feb 2024 86.000 call
CYTK Feb 2024 83.000 put
CYTK Jun 2024 18.000 call
CYTK Feb 2024 97.000 call
CYTK Feb 2024 82.000 put
CYTK Feb 2024 75.000 put
CYTK Feb 2024 81.500 put
CYTK Feb 2024 50.000 call
CYTK Mar 2024 110.000 call
CYTK Mar 2024 75.000 put
BMY Mar 2024 42.000 put
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/24/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
409
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$73.94
High Stock Price Target
$108.00
Low Stock Price Target
$42.00
Potential Upside/Downside
-5.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-6,736.12%
Pretax Margin
-6,739.96%

Debt

Sales & Book Value

Annual Sales
$7.82 million
Book Value
($1.14) per share

Miscellaneous

Free Float
94,328,000
Market Cap
$7.65 billion
Optionable
Optionable
Beta
0.73

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 analysts have issued 1 year target prices for Cytokinetics' stock. Their CYTK share price targets range from $42.00 to $108.00. On average, they predict the company's stock price to reach $73.94 in the next twelve months. This suggests that the stock has a possible downside of 5.2%.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK stock has decreased by 6.6% and is now trading at $78.02.
View the best growth stocks for 2024 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CYTK earnings forecast
.

How can I listen to Cytokinetics' earnings call?

Cytokinetics will be holding an earnings conference call on Tuesday, February 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.11. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to analysts' expectations of $5.67 million. The company's revenue was down 99.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.23) EPS.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.24%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%), First Turn Management LLC (0.82%) and Charles Schwab Investment Management Inc. (0.81%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 2/24/2024 by MarketBeat.com Staff